Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
Latest Information Update: 20 Apr 2023
Price :
$35 *
At a glance
- Drugs Trastuzumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Endometrial cancer; Uterine cancer
- Focus Therapeutic Use
- 19 Jul 2022 Status changed from active, no longer recruiting to completed.
- 01 Dec 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 01 Dec 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.